{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:48Z","timestamp":1792431708336,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Nearly 727\u202f000 individuals in the US died of opioid overdoses between 1999 and 2022. The current workforce of addiction medicine specialists is inadequate to address the scale of this crisis, and primary care clinicians (PCCs) do not feel sufficiently supported to treat opioid use disorder (OUD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate whether an electronic health record\u2013integrated clinical decision support system (CDSS) increases OUD diagnosis and treatment in primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This pragmatic cluster randomized clinical trial was conducted from April 2021 to December 2023. Primary care clinics in 3 health systems in 4 US states were randomized to receive or not receive an electronic health record\u2013integrated CDSS aimed at improving OUD diagnosis and treatment. Eligible patients were aged 18 to 75 years, visited a randomized clinic, and had an OUD diagnosis in the last 2 years, opioid overdose in the last 6 months, or risk score indicating high risk of OUD or opioid overdose. Data were analyzed from September 2023 to October 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>The OUD CDSS provided personalized treatment recommendations to patients and PCCs in intervention clinics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Primary outcomes were likelihood to receive (1) an OUD diagnosis (among high-risk patients without a baseline OUD diagnosis), (2) a naloxone prescription, or (3) a prescription of a medication for OUD (MOUD) or specialty referral, all within 30 days of first eligible (index) visit, and (4) days covered by a MOUD prescription in the 90 days after index.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 10\u202f891 patients meeting eligibility criteria, 5918 (54.3%) were female, and the mean (SD) age was 48.0 (13.9) years. There was no difference in OUD diagnoses within 30 days between groups. Patients in the intervention group had more naloxone orders (80 of 5538 [1.4%] vs 40 of 5353 [0.7%]; odds ratio, 1.76; 95% CI, 1.14-2.72) and orders for MOUDs or treatment referral (775 of 5538 [14.0%] vs 503 of 5353 [9.4%]; odds ratio, 1.48; 95% CI, 1.05-2.08) within 30 days. There were no differences in median (IQR) days covered by MOUD over 90 days postindex between intervention (84 [55-90] days) and usual care (83 [55-90] days; rate ratio, 1.00; 95% CI, 0.93-1.08) or in overdose or death rates during the intervention period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cluster randomized clinical trial, the intervention improved rates of naloxone orders and OUD treatment in primary care but did not affect days covered by a MOUD over 90 days postindex or overdose or death rates. These findings demonstrate an OUD CDSS can help increase access to OUD treatment in primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04198428\">NCT04198428<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.2535","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:00:30Z","timestamp":1752505230000},"page":"1079","source":"Crossref","is-referenced-by-count":16,"title":["Clinical Decision Support System for Primary Care of Opioid Use Disorder"],"prefix":"10.1001","volume":"185","author":[{"given":"Rebecca C.","family":"Rossom","sequence":"first","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Lauren","family":"Crain","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Wright","sequence":"additional","affiliation":[{"name":"Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Olson","sequence":"additional","affiliation":[{"name":"Essentia Institute of Rural Health, Duluth, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Haller","sequence":"additional","affiliation":[{"name":"Essentia Institute of Rural Health, Duluth, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Haapala","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Dehmer","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Hooker","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Solberg","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Borgert-Spaniol","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jule","family":"Gorodisher","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Miley","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Romagnoli","sequence":"additional","affiliation":[{"name":"Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Allen","sequence":"additional","affiliation":[{"name":"Essentia Institute of Rural Health, Duluth, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Tusing","sequence":"additional","affiliation":[{"name":"Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Ekstrom","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Appana","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn M.","family":"Sperl-Hillen","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kobylinski","sequence":"additional","affiliation":[{"name":"Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Huntley","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, Center for the Clinical Trials Network, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McCormack","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Bart","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"29","key":"ioi250039r2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","article-title":"Vital Signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics - 25 states and the District of Columbia, 2019-2020.","volume":"71","author":"Kariisa","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"241","key":"ioi250039r8","first-page":"77330","article-title":"Medications for the Treatment of Opioid Use Disorder.","volume":"87","year":"2024","journal-title":"Fed Regist"},{"issue":"3","key":"ioi250039r9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/00952990.2018.1545131","article-title":"A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.","volume":"45","author":"Kelty","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7","key":"ioi250039r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.20837","article-title":"Physician reluctance to intervene in addiction: a systematic review.","volume":"7","author":"Campopiano von Klimo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ioi250039r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.107012","article-title":"Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care.","volume":"124","author":"Rossom","year":"2023","journal-title":"Contemp Clin Trials"},{"issue":"10","key":"ioi250039r12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.7326\/M16-0317","article-title":"Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) tool for substance use screening in primary care patients.","volume":"165","author":"McNeely","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"ioi250039r13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13722-020-0180-2","article-title":"Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report.","volume":"15","author":"Bart","year":"2020","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"ioi250039r14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.13063\/2327-9214.1049","article-title":"The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration.","volume":"2","author":"Ross","year":"2014","journal-title":"EGEMS (Wash DC)"},{"issue":"1","key":"ioi250039r15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ppe.12711","article-title":"Analysis goals, error-cost sensitivity, and analysis hacking: essential considerations in hypothesis testing and multiple comparisons.","volume":"35","author":"Greenland","year":"2021","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"1","key":"ioi250039r16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"ioi250039r17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069271","article-title":"User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial.","volume":"377","author":"Melnick","year":"2022","journal-title":"BMJ"},{"issue":"12","key":"ioi250039r18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamainternmed.2023.5701","article-title":"Nurse care management for opioid use disorder treatment: the PROUD cluster randomized clinical trial.","volume":"183","author":"Wartko","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"4","key":"ioi250039r19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1353\/cpr.2017.0047","article-title":"Implementing the chronic care model for opioid and alcohol use disorders in primary care.","volume":"11","author":"Watkins","year":"2017","journal-title":"Prog Community Health Partnersh"},{"issue":"11","key":"ioi250039r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.47447","article-title":"Nurse care management of opioid use disorder treatment after 3 years: a secondary analysis of the PROUD cluster randomized clinical trial.","volume":"7","author":"Lapham","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"ioi250039r23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ioi250039r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren\u2019t physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"ioi250039r28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment.","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"21","key":"ioi250039r29","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder.","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"ioi250039r30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"ioi250039r31","first-page":"792","article-title":"Perception of racism explains the difference between Blacks\u2019 and Whites\u2019 level of healthcare trust.","volume":"16","author":"Adegbembo","year":"2006","journal-title":"Ethn Dis"},{"issue":"3","key":"ioi250039r33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/1533256X.2022.2049161","article-title":"Opioid use in indigenous populations: indigenous perspectives and directions in culturally responsive care.","volume":"22","author":"Richer","year":"2022","journal-title":"J Soc Work Pract Addict"},{"issue":"19","key":"ioi250039r34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6619a1","article-title":"Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas - United States.","volume":"66","author":"Mack","year":"2017","journal-title":"MMWR Surveill Summ"},{"issue":"3","key":"ioi250039r35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3122\/jabfm.2023.230308R1","article-title":"Barriers and facilitators to using a clinical decision support tool for opioid use disorder in primary care.","volume":"37","author":"Hooker","year":"2024","journal-title":"J Am Board Fam Med"},{"issue":"6","key":"ioi250039r36","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3122\/jabfm.2021.06.210126","article-title":"Clinician perceptions about a decision support system to identify and manage opioid use disorder.","volume":"34","author":"Solberg","year":"2021","journal-title":"J Am Board Fam Med"},{"key":"ioi250039r37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","article-title":"Stigma at every turn: health services experiences among people who inject drugs.","volume":"57","author":"Paquette","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"6","key":"ioi250039r38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1370\/afm.2470","article-title":"Capacity to address social needs affects primary care clinician burnout.","volume":"17","author":"Kung","year":"2019","journal-title":"Ann Fam Med"},{"issue":"16","key":"ioi250039r39","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMra2302878","article-title":"Burnout, depression, and diminished well-being among physicians.","volume":"391","author":"Guille","year":"2024","journal-title":"N Engl J Med"},{"key":"ioi250039r1","unstructured":"US Centers for Disease Control. Understanding the opioid overdose epidemic. Accessed March 25, 2025. https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html"},{"key":"ioi250039r3","unstructured":"Ferragamo? M, Klobucista? C. Fentanyl and the U.S. opioid epidemic. Accessed October 28, 2024. https:\/\/www.cfr.org\/backgrounder\/fentanyl-and-us-opioid-epidemic"},{"key":"ioi250039r4","unstructured":"Spencer MR, Garnett MF, Mini\u00f1o AM. Drug Overdose Deaths in the United States, 2002-2022. Accessed April 10, 2025. https:\/\/stacks.cdc.gov\/view\/cdc\/135849"},{"key":"ioi250039r5","unstructured":"Substance Abuse and Mental Health Services Administration. Table 5.22B \u2013 received medication-assisted treatment (MAT) for opioid use in past year: among people aged 12 or older; received MAT for opioid use in past year: among people aged 12 or older with past year opioid use disorder; by demographic characteristics, percentages, 2022 and 2023. Accessed March 25, 2025. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47100\/NSDUHDetailedTabs2023\/NSDUHDetailedTabs2023\/2023-nsduh-detailed-tables-sect5pe.htm#tab5.22b"},{"key":"ioi250039r6","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health. Accessed March 25, 2025. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"ioi250039r7","unstructured":"Statista. Number of active primary care physicians in the U.S. in 2025, by field of specialty. Accessed December 6, 2024. https:\/\/www.statista.com\/statistics\/1488562\/number-of-us-active-primary-care-physicians-by-field\/"},{"key":"ioi250039r21","unstructured":"Milgram? A. DEA announces important change to registration requirement. Accessed October 28, 2024. https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/A-23-0020-Dear-Registrant-Letter-Signed.pdf"},{"key":"ioi250039r22","unstructured":"US Centers for Medicare & Medicaid Services; Medicare Learning Network. Opioid treatment programs (OTPs): Medicare billing and payment fact sheet. Accessed April 10, 2025. https:\/\/www.cms.gov\/sites\/default\/files\/2020-12\/ICNMLN8296732_2020_12_OTP_Billing_and_Payment_Print_Friendly_508.pdf"},{"key":"ioi250039r25","unstructured":"Substance Abuse and Mental Health Services Administration. The opioid crisis and the Black\/African American population: an urgent issue. Accessed October 28, 2024. https:\/\/store.samhsa.gov\/product\/opioid-crisis-and-blackafrican-american-population-urgent-issue\/pep20-05-02-001"},{"key":"ioi250039r26","unstructured":"Substance Abuse and Mental Health Services Administration. The opioid crisis and the Hispanic\/Latino population: an urgent issue. Accessed October 28, 2024. https:\/\/library.samhsa.gov\/product\/opioid-crisis-and-hispaniclatino-population-urgent-issue\/pep20-05-02-002"},{"key":"ioi250039r27","unstructured":"Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2017, data on substance abuse treatment facilities. Accessed October 28, 2024. https:\/\/www.samhsa.gov\/data\/report\/national-survey-substance-abuse-treatment-services-n-ssats-2017-data-substance-abuse"},{"key":"ioi250039r32","unstructured":"Agency for Healthcare Research and Quality. Blacks experiencing fast-rising rates of overdose deaths involving synthetic opioids other than methadone. Accessed October 28, 2024. https:\/\/www.ahrq.gov\/sites\/default\/files\/wysiwyg\/research\/findings\/nhqrdr\/dataspotlight-opioid.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2836529\/jamainternal_rossom_2025_oi_250039_1756399027.22009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:00:56Z","timestamp":1756825256000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2836529"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.2535","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}